HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Relationship of posttransplantation erythrocytosis to hypercalcemia in renal transplant recipients.

AbstractExperimental studies have demonstrated that calcium is an essential molecule in modulation of erythropoiesis. The aim of this study was to investigate the role of serum calcium levels on the development of posttransplantation erythrocytosis (PTE) among renal transplant recipients. We enrolled 155 patients (36 females/119 males; mean age, 34.9 +/- 9.7 years) with normal graft function who underwent renal transplantation between 1999 and 2002. All of the demographic features and various laboratory parameters were retrospectively analyzed as possible factors associated with erythrocytosis. PTE appeared in 43 (27.7%) patients during the follow-up period. Sixty-three (40.6%) patients developed hypercalcemia (corrected serum calcium level > or =10.2 mg/dL). Serum calcium levels tended to increase in patients with PTE, but significantly decreased in patients without PTE (10.6 +/- 0.6 vs 9.8 +/- 0.5 mg/dL; P < .0001). Similarly, hypercalcemia was more common among patients with PTE compared with patients without PTE (74.4% vs 27.7%; P < .0001). Hypercalcemic patients had a significantly higher frequency of PTE than normocalcemic patients (50.7% vs 11.9%; P < .0001). There were no differences in other laboratory and demographic data between the patients with and without PTE (P > .05). These findings suggest that hypercalcemia may lead to increased PTE in renal transplant recipients.
AuthorsA Akcay, M Kanbay, B Huddam, C A Usluogullari, Z Arat, F N Ozdemir, M Haberal (Affiliation: Department of Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey. aliakcay1971 at yahoo.com)
JournalTransplantation proceedings (Transplant Proc) Vol. 37 Issue 7 Pg. 3103-5 (Sep 2005) ISSN: 0041-1345 [Print] United States
PMID16213320 (Publication Type: Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Calcium
Topics
  • Adult
  • Calcium (blood)
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Hypercalcemia (complications, epidemiology)
  • Immunosuppressive Agents (therapeutic use)
  • Kidney Transplantation (adverse effects, immunology, physiology)
  • Male
  • Middle Aged
  • Polycythemia (complications, epidemiology)
  • Postoperative Complications (blood)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD